Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)

16 november 2026 uppdaterad av: Tuberculosis Research Centre, India

A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin

This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.

Studieöversikt

Detaljerad beskrivning

Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)

Studietyp

Interventionell

Inskrivning (Beräknad)

2500

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Andhra Pradesh
      • Guntur, Andhra Pradesh, Indien, 522503
        • Rekrytering
        • All India Institute of Medical Sciences(AIIMS), Mangalagiri
        • Kontakt:
    • Assam
      • Guwahati, Assam, Indien, 781101
        • Aktiv, inte rekryterande
        • All India Institute of Medical Sciences, Guwahati
    • Gujarat
      • Rajkot, Gujarat, Indien, 360001
        • Har inte rekryterat ännu
        • Govt. PDU Medical College
        • Kontakt:
      • Surat, Gujarat, Indien, 395001
        • Aktiv, inte rekryterande
        • Govt. Medical College and NCH
    • Maharashtra
      • Mumbai, Maharashtra, Indien, 400008
        • Rekrytering
        • Grant Govt. Medical College & Sir JJ Group of Hospitals
        • Kontakt:
      • Nagpur, Maharashtra, Indien
        • Har inte rekryterat ännu
        • All India Institute Of Medical Sciences, Nagpur
        • Kontakt:
    • Meghālaya
      • Shillong, Meghālaya, Indien, 793018
        • Rekrytering
        • North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
        • Kontakt:
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Indien, 110030
        • Har inte rekryterat ännu
        • National Institute of TB and Respiratory Diseases
        • Kontakt:
    • Odisha
      • Bhubaneswar, Odisha, Indien, 751019
        • Aktiv, inte rekryterande
        • All India Institute of Medical Sciences (AIIMS), Bhubaneswar
      • Bhubaneswar, Odisha, Indien, 751001
        • Aktiv, inte rekryterande
        • Post Graduate Institute of Medical Education & Research, Capital Hospital
    • Tamil Nadu
      • Chennai, Tamil Nadu, Indien, 600031
        • Rekrytering
        • ICMR - National Institute for Research in Tuberculosis
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Dr PK Bhavani, MBBS., MPH., PGDBEME
        • Huvudutredare:
          • Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
        • Underutredare:
          • Dr R Balaji, MBBS., MD.,
    • Telangana
      • Hyderabad, Telangana, Indien, 500038
        • Rekrytering
        • Govt. General and Chest Hospital, Osmania Medical College
        • Kontakt:
    • Uttar Pradesh
      • Agra, Uttar Pradesh, Indien, 282002
        • Rekrytering
        • Sarojini Naidu Medical College
        • Kontakt:
      • Allahābād, Uttar Pradesh, Indien, 211002
        • Rekrytering
        • Moti Lal Nehru Medical College
        • Kontakt:
      • Lucknow, Uttar Pradesh, Indien, 226003
        • Rekrytering
        • King George Medical University
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

14 år till 70 år (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Individuals aged equal or above 14 years.
  2. Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
  3. Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
  4. If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
  5. Willing to follow the trial procedures

Exclusion Criteria:

  1. Body weight less than 30 kg in adults

  2. Anti-TB treatment, >14 days for the current illness

  3. Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA

  4. Patients with serious forms of Extra-pulmonary TB

  5. HIV Patients on second line ART regimens.

  6. Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities

    • ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
    • Serum Creatinine >1.2 mg/dl.
  7. Pregnant or lactating mothers

  8. Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability

  9. Patients with h/o of concomitant medications which may interfere with study drugs

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: 2H R25 ZE /4 H R10 E

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol

Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

Experimentell: 2 H R25 ZE/ 4 H R25 E

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol

Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol

Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

Experimentell: 2 H R25 ZE L/2 H R25 E L

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg)

Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin.

Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs.

Aktiv komparator: 2 H R10 ZE /4H R10 E

Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol

Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol

Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Tidsram: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of patients with grade 3 or 4 adverse drug reactions.
Tidsram: Through treatment completion, an average of 24 weeks
Through treatment completion, an average of 24 weeks
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Tidsram: Through treatment completion, an average of 24 weeks
Through treatment completion, an average of 24 weeks
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Tidsram: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Tidsram: At 1st Month
At 1st Month
The cost effectiveness of different treatment regimens
Tidsram: Through treatment completion, an average of 24 weeks

Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB.

Through treatment completion, an average of 24 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
  • Huvudutredare: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

6 juni 2026

Primärt slutförande (Beräknad)

1 december 2028

Avslutad studie (Beräknad)

1 december 2029

Studieregistreringsdatum

Först inskickad

9 november 2026

Först inskickad som uppfyllde QC-kriterierna

16 november 2026

Första postat (Faktisk)

18 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 november 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera